ONO-1110 + Placebo

Phase 2Active
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Social Anxiety Disorder (SAD)

Conditions

Social Anxiety Disorder (SAD)

Trial Timeline

Jan 16, 2025 → Oct 31, 2026

About ONO-1110 + Placebo

ONO-1110 + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Social Anxiety Disorder (SAD). The current trial status is active. This product is registered under clinical trial identifier NCT06805565. Target conditions include Social Anxiety Disorder (SAD).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT06752603Phase 2Recruiting
NCT06752590Phase 2Recruiting
NCT06708416Phase 2Active
NCT06805565Phase 2Active
NCT06792136Phase 2Active

Competing Products

20 competing products in Social Anxiety Disorder (SAD)

See all competitors
ProductCompanyStageHype Score
LY686017 + paroxetine + placeboEli LillyPhase 2
52
atomoxetine + placeboEli LillyPhase 2/3
65
Cariprazine + PlaceboAbbVieApproved
85
QuetiapineAstraZenecaApproved
85
quetiapineAstraZenecaPhase 3
77
quetiapineAstraZenecaPhase 2/3
65
Seroquel + Sugar PillAstraZenecaPhase 3
77
quetiapineAstraZenecaApproved
85
Pristiq + PlaceboPfizerApproved
84
Venlafaxine ERPfizerPhase 3
76
Ziprasidone + SertralinePfizerPhase 2
51
Sertraline + PlaceboPfizerApproved
84
NefazodoneBristol Myers SquibbApproved
84
EscitalopramLundbeckApproved
82
Cipralex + PlaceboLundbeckPhase 2
49
BHV-0223 + PlaceboBiohavenPhase 2/3
60
VQW-765 + PlaceboVanda PharmaceuticalsPhase 3
69
PH94BVistagen TherapeuticsPhase 3
69
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal SprayVistagen TherapeuticsPhase 2
44
PH94B Nasal Spray + Placebo Nasal SprayVistagen TherapeuticsPhase 3
69